About this trial
Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.
Eligibility criteria
Qualifiers
PsA patients as defined by CASPAR criteria
Patients must be able to comply with the visit schedule, treatment plan, laboratory tests and other study procedures
Patients must be given informed consent
Disqualifiers
History of other arthritis within the last 12 months
Concomitant disease with acute or chronic infectious diseases
Pregnancy or laction
Poorly tolerated with venipuncture required for blood sampling during the study
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Nanjing Medical University
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Sponsor institution